Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study

Table 5 Multivariable analyses of anthracycline-treated patients, N = 99*

		DFS		OS
		HR (95% CI)	P	HR (95% CI)	P
TIMP-1	Continuous variable	1.75 (1.00-3.07)	0.05	4.19 (1.67-10.51)	0.002
	High vs. low	1.48 (0.84-2.61)	0.17	2.59 (1.14-5.88)	0.02
Age	41-55 years vs. ≤ 40 years	0.68 (0.37-1.25)	0.22	0.80 (0.37-1.72)	0.57
Tumor size	Stage 2 (> 2 cm) vs. stage 1 (≤ 2 cm)	2.13 (0.91-4.98)	0.13	3.63 (0.82-16.13)	0.14
	Stage 3 (>5 cm or chest wall/skin involvement) vs. stage 1 (≤ 2 cm)	2.31 (0.87-6.11)		2.77 (0.54-14.14)
Grade	Unknown vs. poor	0.90 (0.43-1.92)	0.88	0.16 (0.02-1.21)	0.06
	Well/moderate vs. poor	0.82 (0.35-1.88)		1.11 (0.39-3.15)

* Analyses stratified for hormone receptor status, nodal status and RT on the axilla. The results for age, tumor size and grade are from the base model not including TIMP-1. TIMP-1 was added separately as a continuous variable and then as a dichotomized one. The coefficients for age, tumor size and grade were similar with TIMP-1 included.

ISSN: 1471-2407